The use of anticholinergic drugs for smoking cessation: a pilot study.
A pilot study of 500 cases drawn from a total population of 3,700 patients reports on a smoking cessation program in a private practice clinic. A new protocol offers promise for treatment based on an initial injected dose of atropine, scopolamine, and chlorpromazine administered subcutaneously to eliminate physiological withdrawal symptoms, followed by a 2-week oral medication regimen, and follow-up every 2 months for a 12-month period. The study held that 92.1% of the male patients and 80.7% of female patients remained nonsmokers at the end of 2 months; 42.3% of the men and 36.9% of the women remained nonsmokers at the end of 12 months, a cumulative total of 39.8%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001285:Atropine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009042:Motivation; D010276:Parasympatholytics / Q000627:therapeutic use*; D010865:Pilot Projects; D012189:Retrospective Studies; D012601:Scopolamine / Q000627:therapeutic use; D000074606:Smoking Prevention; D013997:Time Factors; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000523:psychology
D010276:Parasympatholytics; D001285:Atropine; D012601:Scopolamine